Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283178 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01283178 is a Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 3 participants.
The verdict
NCT01283178, a Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. CT and PET scans and treatment-planning systems may help in planning radiation therapy. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with cisplatin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of intensity-modulated image guided adaptive radiation therapy when given together with cisplatin in treating patients with locally advanced head and neck squamous cell cancer
Interventions
- DRUG cisplatin
- RADIATION intensity-modulated radiation therapy
- PROCEDURE positron emission tomography/computed tomography
- OTHER 3'-deoxy-3'-[18F]fluorothymidine
- RADIATION image-guided adaptive radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283178
The ClinicalTrials.gov registry entry for NCT01283178 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT01283178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283178 about?
NCT01283178 is a clinical study titled "Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC". RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. CT and PET scans and treatment-planning systems may help in planning radiation therapy. Drugs used in chemotherapy, such as cisplati...
What is the current status of trial NCT01283178?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-07. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01283178?
The interventions under investigation include: cisplatin (DRUG), intensity-modulated radiation therapy (RADIATION), positron emission tomography/computed tomography (PROCEDURE), 3'-deoxy-3'-[18F]fluorothymidine (OTHER), image-guided adaptive radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01283178?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.